Author: David Katzelnick, MD
Director, Healthcare Technology Systems, Inc. Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health Dr. Katzelnick has disclosed that he is on the speaker's bureau for Abbott, Forest, GlaxoSmithKline, Lilly, Novartis, Pfizer, Pharmacia, and UCB; is a consultant for Abbott, Forest, MacArthur Foundation, Merck, Novartis, Organon, Robert Wood Johnson Foundation, UCB, Shire, and Wyeth; has received grant/research support from Abbott, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer, and Solvay; is a minor stock shareholder in Johnson & Johnson; and is a principal in the company Healthcare Technology Systems, Inc. Dr. Carlat detected no bias in the content of this interview as a result of these relationships.